...I have not seen any information on the web about GPI-1046. Has any body out there kept on track of the clinical trials?... Hi, The following are my e-mail messages or parts thereof, from last fall/winter regarding Guilford's compound GPI 1046, developed at John's Hopkins and Guilford, and then licensed to Amgen, who named it NIL-A, AMGEN of Thousand Oaks, CA. It is in Phase I trials in Europe. Go to: http://www.amgen.com/product/Pipeline.html to keep up-to-date, but they are keeping their cards fairly close to the chest right now, and it will be years before it comes to market, if it makes it past all the trials. Make no mistake, I'm very excited about it and other therapies under development, and would be willing to be part of the Phase II-IV trials, if it continues to show promise and safety--but, reality is reality. Still, I believe that something much better than drug therapy is in our sites. Keep the faith, Charlotte ------------------- "Hi, It's not called GPI 1046 at Amgen: 1046 is still being used at John Hopkins and Guilford as a research tool and not as a commercial product: The compound, neuroimmunophilin compound, was licensed to Amgen ... http://www.amgen.com/product/Pipeline.html Neuroimmunophilins Phase 1 [ top ] Guilford Pharmaceuticals and Amgen have initiated the first clinical testing of a class of compounds known as neuroimmunophilins. The neuroimmunophilin compounds are being developed to promote nerve regeneration and repair neurodegenerative disorders. In preclinical studies, including models of Parkinson's disease, neuroimmunophilins demonstrated potential to promote nerve regeneration and repair. In 1997, Amgen licensed from Guilford worldwide rights for the neuroimmunophilins, a novel class of small molecule neurotrophic agents that may represent a new approach in the treatment of neurodegenerative disorders. Me," -- Charlotte A. Mancuso *************************************************** For advocacy, medical, and other PD-related material, go to: http://www.onelist.com/subscribe/CurePD-NorCal ------------------------------------------------ BALTIMORE (Dow Jones)--Guilford Pharmaceuticals Inc. (GLFD) received a $5 million milestone payment from Amgen Inc. (AMGN) for clinical developments in the companies' neuroimmunophilin collaboration. In a press release Thursday, Guilford said it earned the payment when Amgen filed an Investigational New Drug application in the U.S. for the ligands, which have demonstrated, in animal testing, the ability to promote re-growth and repair of damaged nerves. The companies seek to develop neuroimmunophilin ligands for Parkinson's disease, Alzheimer's disease, stroke, peripheral neuropathies, traumatic brain injuries, traumatic spinal cord injuries, multiple sclerosis, ophthalmic applications, and two additional undisclosed nonneurological indications. Under their agreement, Guilford is receiving $13.5 million in research funding over three years, will receive royalties on any future product sales and is eligible to receive up to $392 million in development milestones. Amgen is responsible for conducting all clinical development, manufacturing and marketing. -Michael Squires; Dow Jones Newswires; 201-938-5400 1999 Dow Jones & Company, Inc. All Rights Reserved. Dennis Nestler wrote: > What a fine Saturday night this is, I got the whole place to myself. I'm > trying to file all the e-mail I've kept over the past couple of years. I ran > across a post from William Levinson dated 7-16-97 in which he asked if there > was any information on the clinical trials of GPI-1046. > > Bill also gave the List two sites to read which are...... > > http://www.parkinson org/texthtms/tcure.htm > http://www.mhsource.com/edu/psytimes/p970401a.html > > I have not seen any information on the web about GPI-1046. Has any body out > there kept on track of the clinical trials? > > Now all I have to file away is 299 e-mails. > > Dennis > 58/52 -- Charlotte A. Mancuso *************************************************** For advocacy, medical, and other PD-related material, go to: http://www.onelist.com/subscribe/CurePD-NorCal